Abeona Therapeutics Inc ABEO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)
Trading Information
- Previous Close Price
- $5.25
- Day Range
- $4.99–5.25
- 52-Week Range
- $4.00–7.65
- Bid/Ask
- $5.04 / $5.06
- Shares Outstanding
- 57.18M
- Market Cap
- $286.49M
- Volume/Avg
- 1M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 226
Valuation
|
Metric
|
ABEO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.24 |
Price/Sales | 12.17 |
Price/Cash Flow | — |
Price/Earnings
ABEO
Financial Strength
|
Metric
|
ABEO
|
|---|---|
Quick Ratio | 6.32 |
Current Ratio | 6.63 |
Interest Coverage | −24.44 |
Quick Ratio
ABEO
Profitability
|
Metric
|
ABEO
|
|---|---|
Return on Assets (Normalized) | −25.85% |
Return on Equity (Normalized) | −36.23% |
Return on Invested Capital (Normalized) | −32.65% |
Return on Assets
ABEO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SLBqW^> | LOCK|vQJ! | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&@mPy?T | LOCK|^@pc& | $76B | |||
| Moderna Inc
MRNA
| LOCK|xt?TB^ | LOCK|pN | $75B | |||
| argenx SE ADR
ARGX
| LOCK|#lQqjv | LOCK|^^ | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X$!t^fl | LOCK|<s | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|V%rltD< | LOCK|X?^h | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!@<Pjf% | LOCK|tfV>< | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|%&t&@$ | LOCK|!v | $24B | |||
| Incyte Corp
INCY
| LOCK|#>^@Vs% | LOCK|qM | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$<W&RY | LOCK|>p | $15B |
United States